David A Huff, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 9900 W M 21 Ste 104, Ovid, MI 48866 Phone: 989-862-4224 Fax: 989-862-4382 |
News Archive
In 1955 medical literature first defined and described M.E., an illness that had probably been with us for hundreds of years. But with a wide range of symptoms, no diagnostic test and much misunderstanding about its cause, people with M.E. often had to struggle to manage the illness with little support from specialist services.
While you are browsing online, you could be squandering memories - or losing important information.
The prescription of testosterone supplementation for cardiovascular health, sexual function, physical function, mood, or cognitive function in men with "low T" is not supported by clinical trials data, conclude researchers who describe a review of more than 200 clinical trials published Sept. 21 in PLOS One.
Eisai Co., Ltd. has announced that its U.S. subsidiary Eisai Inc. has received approval from the U.S. Food and Drug Administration (FDA) for an additional indication for Eisai's in-house developed novel anticancer agent Lenvima (lenvatinib mesylate) in combination with everolimus for the treatment of patients with advanced renal cell carcinoma following one prior anti-angiogenic therapy.
Teva Pharmaceutical Industries Ltd and Barr Pharmaceuticals, Inc. announced today that they have signed a definitive agreement under which Teva will acquire Barr, the fourth largest generic drug company worldwide.
› Verified 7 days ago